Search - tctmd.com

Displaying 281 - 300 of 901

Sort: Relevancy | Date

News Daily News

Sex Differences Diminish With Third-Generation TAVR Device

L.A. McKeown

January 05, 2018

Presentation

Sex-Specific Outcomes of TAVR With the SAPIEN 3 Valve

January 05, 2018

News Daily News

Novel Repositionable TAVR Device Sees Low Pacemaker Rates and Few Leaks

Shelley Wood

December 19, 2017

News Daily News

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Caitlin E. Cox

November 30, 2017

News Conference News AHA 2017

More Support for TMVR After Failed Mitral Bioprostheses

Yael L. Maxwell

November 23, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

Presentation TCT 2017

How to Treat Severe PR in the Large RVOT Using Melody or Sapien Valves

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Daniel S Levi

November 01, 2017

Presentation TCT 2017

Current Results of Transcatheter PV Therapy: Melody and Sapien

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Thomas K. Jones

November 01, 2017

Presentation TCT 2017

SAPIEN 3 Procedural Pearls (Including Optimal Sizing Algorithms)

Presenter: Susheel K. Kodali

October 31, 2017

Presentation TCT 2017

SAPIEN 3 TAVR Technology Review (Including Sapien 3 ULTRA) and Clinical Program Updates

Presenter: John G. Webb

October 31, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

Taped and Edited Live-Case of the Use of a TriGuard Cerebral Protection Device During TAVR With Sapien 3

Presenter: Francesco Saia, Gerhard C. Schuler, Pieter R. Stella

October 31, 2017

Presentation TCT 2017

Impella and Rotablation-assisted Bifurcation PCI Following Previous Edwards SAPIEN 3 TAVR

Presenter: Mohamed Ahmed Sobhy, Faisal Khan

October 30, 2017

Presentation TCT 2017

Percutaneous Mitral Valve-in Valve Implantation With SAPIEN 3 Prosthesis Using an Anterograde Transvenous Transseptal Approach

Presenter: Vasilis Babaliaros, Shmuel Banai, Caterina Gandolfo

October 30, 2017

Presentation TCT 2017

Case #8: Transseptal Mitral ViMAC With SAPIEN 3 (With Discussion)

Presenter: Mayra Guerrero, Nicolas M. Van Mieghem

October 30, 2017

Presentation TCT 2017

Case #4: Trans-septal Mitral ViV With SAPIEN 3 (With Discussion)

Presenter: Mayra Guerrero, Nicolas M. Van Mieghem, Mackram F. Eleid

October 30, 2017

Advertisement

Sex Differences Diminish With Third-Generation TAVR Device

Sex-Specific Outcomes of TAVR With the SAPIEN 3 Valve

Novel Repositionable TAVR Device Sees Low Pacemaker Rates and Few Leaks

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

More Support for TMVR After Failed Mitral Bioprostheses

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

How to Treat Severe PR in the Large RVOT Using Melody or Sapien Valves

Current Results of Transcatheter PV Therapy: Melody and Sapien

SAPIEN 3 Procedural Pearls (Including Optimal Sizing Algorithms)

SAPIEN 3 TAVR Technology Review (Including Sapien 3 ULTRA) and Clinical Program Updates

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Live From Denver: TCT 2017, Day Two

Taped and Edited Live-Case of the Use of a TriGuard Cerebral Protection Device During TAVR With Sapien 3

Impella and Rotablation-assisted Bifurcation PCI Following Previous Edwards SAPIEN 3 TAVR

Percutaneous Mitral Valve-in Valve Implantation With SAPIEN 3 Prosthesis Using an Anterograde Transvenous Transseptal Approach

Case #8: Transseptal Mitral ViMAC With SAPIEN 3 (With Discussion)

Case #4: Trans-septal Mitral ViV With SAPIEN 3 (With Discussion)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content